Published in J Pharmacol Exp Ther on July 06, 2015
Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein. Drug Metab Dispos (2015) 0.75
Contrasting roles of the ABCG2 Q141K variant in prostate cancer. Exp Cell Res (2017) 0.75
Application of JC1 for non-toxic isolation of cells with MDR transporter activity by flow cytometry. PLoS One (2017) 0.75
Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier. Sci Rep (2016) 0.75
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Drug-resistant epilepsy. N Engl J Med (2011) 3.82
Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci (2005) 3.19
HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 2.87
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol (2005) 2.43
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer (2003) 2.33
MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia (1995) 1.97
P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol (2013) 1.82
Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther (2009) 1.77
ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol (2008) 1.65
P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med (2010) 1.62
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res (2009) 1.46
The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry (2006) 1.45
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem (2009) 1.25
A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol (2009) 1.22
Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol (2004) 1.21
Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). Biochemistry (2002) 1.12
Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain (2012) 1.06
Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci (2011) 1.00
Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods (2010) 0.99
N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos (2010) 0.98
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci U S A (2013) 0.96
(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP. Nucl Med Biol (2013) 0.93
A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J Cereb Blood Flow Metab (2012) 0.91
Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos (2013) 0.88
Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. Neuropathol Appl Neurobiol (2006) 0.87
Use of the cassette-dosing approach to assess brain penetration in drug discovery. Drug Metab Dispos (2012) 0.86
Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier. Mol Pharm (2013) 0.82
Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. J Labelled Comp Radiopharm (2013) 0.81
Radiosynthesis of [2-(11)C-carbonyl]dantrolene using [(11)C]phosgene for PET. Appl Radiat Isot (2010) 0.80
BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol Pharmacol (1996) 0.79
Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats. Drug Metab Dispos (2014) 0.77
Synthesis and ABCG2 inhibitory activity of novel fumitremorgin C analogs--specificity and structure activity correlations. Med Chem (2013) 0.76
Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.76